PTCT Share Price Performance
US$78.47
35.24 (81.52%)
0.7% overvalued intrinsic discount
US$77.93
Fair Value
Price US$78.47
AnalystConsensusTarget US$77.93
AnalystHighTarget US$120.00
AnalystLowTarget US$44.00
Fair ValueUS$77.93
Share Pricen/a
PTC Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
PTCT Community Narratives
AN
Fair Value US$77.93 0.7% overvalued intrinsic discount
Upcoming Launches Will Drive Rare Disease Momentum Despite Ongoing Regulatory Risks
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$102.62 23.5% undervalued intrinsic discount
Aging Population Trends Will Expand Rare Therapy Markets Despite Risks
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$44 78.3% overvalued intrinsic discount
Rising Healthcare Cost Containment And Delayed Approvals Will Erode Margins
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Upcoming Launches Will Drive Rare Disease Momentum Despite Ongoing Regulatory Risks
Key Takeaways Broad approvals and strong launch strategy for Sephience position the company to accelerate growth and improve profitability in rare disease markets worldwide. Advancing pipeline and strategic capital moves enhance revenue stability, earnings visibility, and highlight potential undervaluation versus long-term growth prospects.Read more
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$77.93
0.7% overvalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
-6.08% p.a.
Profit Margin
15.43%
Future PE
38.55x
Share price in 2028
US$96.79
Aging Population Trends Will Expand Rare Therapy Markets Despite Risks
Key Takeaways Accelerated adoption of key therapies, global expansion, and a robust rare disease portfolio position the company for sustained revenue and margin growth. Strategic partnerships, disciplined operations, and business development readiness enhance flexibility for value-creating deals and expanding innovative treatment pipelines.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$102.62
23.5% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
-9.24% p.a.
Profit Margin
15.56%
Future PE
53.45x
Share price in 2028
US$126.48
Rising Healthcare Cost Containment And Delayed Approvals Will Erode Margins
Key Takeaways Increasing regulatory delays, pricing constraints, and competition threaten PTC's ability to profitably launch and sustain new rare disease therapies. Reliance on a shrinking product portfolio and persistent cash burn heighten the risk of revenue decline and potential shareholder dilution.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$44
78.3% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
-21.9% p.a.
Profit Margin
16.25%
Future PE
34.49x
Share price in 2028
US$54.29
Recently Updated Narratives
AN
Upcoming Launches Will Drive Rare Disease Momentum Despite Ongoing Regulatory Risks
Fair Value: US$77.93 0.7% overvalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Healthcare Cost Containment And Delayed Approvals Will Erode Margins
Fair Value: US$44 78.3% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Population Trends Will Expand Rare Therapy Markets Despite Risks
Fair Value: US$102.62 23.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
PTC Therapeutics, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 9.36
- 71.71%
- 42.25%
- -1,520.5%
About PTCT
- Founded
- 1998
- Employees
- 939
- CEO
- WebsiteView website
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington’s disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich’s ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
